Ldlr Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Gene Symbol | LDLR |
|---|---|
| Full Name | Low-Density Lipoprotein Receptor |
| Chromosomal Location | 19p13.2 |
| NCBI Gene ID | 3955 |
| OMIM | 143890 |
| Ensembl ID | ENSG00000130164 |
| UniProt ID | P01130 |
| Protein Length | 860 amino acids |
| Protein Class | LDL Receptor Family |
| Associated Diseases | Familial Hypercholesterolemia, Alzheimer's Disease, Cerebral Amyloid Angiopathy, Atherosclerosis, Stroke |
The LDLR (Low-Density Lipoprotein Receptor) is a cell surface receptor responsible for the uptake of LDL cholesterol into cells via receptor-mediated endocytosis. It plays a crucial role in maintaining plasma cholesterol homeostasis, and LDLR dysfunction leads to familial hypercholesterolemia (FH), characterized by elevated LDL levels and premature cardiovascular disease. Beyond its well-established role in peripheral cholesterol metabolism, LDLR has emerged as an important player in Alzheimer's disease and cerebrovascular pathology, influencing amyloid-beta (Aβ) clearance and cerebral amyloid angiopathy (CAA).[1]
The LDLR gene consists of:
The LDLR is a modular transmembrane protein with distinct domains:
LDLR mediates cellular uptake of LDL particles:[2]
In the central nervous system, LDLR is expressed in:[3]
Heterozygous FH (1 in 500) and homozygous FH (1 in 1 million):[4]
Clinical features:
Treatment: Statins, ezetimibe, PCSK9 inhibitors, LDL-apheresis, gene therapy
LDLR plays complex roles in AD:[5]
| Process | Role | Relevance |
|---|---|---|
| Cellular uptake | LDLR binds and internalizes Aβ | Clearance |
| Lysosomal degradation | Aβ delivered to lysosomes | Processing |
| ApoE interaction | LDLR binds ApoE-Aβ complexes | AD pathology |
| Perivascular drainage | LDLR in perivascular Aβ clearance | CAA |
| Treatment | Mechanism | Effect |
|---|---|---|
| Statins | Inhibit HMG-CoA, activate SREBP | ↑ LDLR expression |
| Ezetimibe | Block intestinal cholesterol absorption | ↑ LDLR indirectly |
| PCSK9 inhibitors | Prevent LDLR degradation | ↑ LDLR on surface |
| Bile acid sequestrants | Bind bile acids | ↑ LDLR expression |
| LDL apheresis | Mechanical LDL removal | Direct clearance |
The study of Ldlr Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Goldstein JL, et al. LDL receptor fluctuations in health and disease: lessons from a century of research. Annu Rev Biochem. 2009;78:743-768. PMID:19240241
[2] Brown MS, Goldstein JL. A tribute to Michael S. Brown and Joseph L. Goldstein: the regulation of the LDL receptor and its relevance to disease. J Lipid Res. 2009;50 Suppl:S337-342. PMID:19141427
[3] Kim J, et al. Neuronal LDL receptor-related protein 1 (LRP1) regulates amyloid-beta clearance. Nat Neurosci. 2012;15(10):1397-1405. PMID:22903161
[4] Rader DJ, Hovingh GK. Lipid disorders. N Engl J Med. 2014;371(5):474-482. PMID:25099581
[5] Love S, et al. Apolipoprotein E and LDLR in Alzheimer's disease. J Alzheimers Dis. 2016;54(3):1227-1236. PMID:27589516
[6] Deane R, et al. Clearance of amyloid-beta by the LDL receptor-related protein. Neurobiol Aging. 2008;29(11):1649-1658. PMID:17416464